Journal: Cancer Biomarkers: Section A of Disease Markers

Article Title: GABPα inhibits tumor progression and angiogenesis via a novel 18-bp indel within VEGF promoter in breast cancer

doi: 10.3233/CBM-230541

Figure Lengend Snippet: GABPα inhibited angiogenesis of breast cancer cells by regulating VEGF. (a) The mRNA expression of GABPα and VEGF in MDA-MB-231 cells with GABPα overexpression or depletion. (b) The secretory VEGF protein levels in supernatant in stable MDA-MB-231 cells with GABPα overexpression or depletion by ELISA. (c-d) The protein level of GABPα and VEGF in MDA-MB-231 cells with GABPα overexpression or depletion. (e) Effects of conditional medium from GABPα overexpressed or depleted MDA-MB-231 cells on tube formation in HUVECs. Quantification of tubes was displayed as bar graph. (f) Effects of conditional medium from GABPα overexpressed or depleted MDA-MB-231 cells on neovascularization by CAM assay. Bar graph showed the quantified blood vessels. Data are expressed as means ± SEM from at least three experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: The associated primary antibodies used in IHC assay are included: GABPα (1:100 dilution, Santa Cruz Biotechnology Inc), VEGF-A (1:100 dilution, BOSTER), CD31 (1:100 dilution, CUSABIO).

Techniques: Expressing, Over Expression, Enzyme-linked Immunosorbent Assay, Chick Chorioallantoic Membrane Assay

Journal: Reproductive Biology and Endocrinology : RB&E

Article Title: linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer

doi: 10.1186/s12958-022-00995-2

Figure Lengend Snippet: Antibodies used in western blot and IHC experiments

Article Snippet: The primary antibody against VEGFA (bs-4572R, Bioss, Beijing, China) was diluted with 1% donkey serum (1:200) and then added in each well.

Techniques: Western Blot

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Placement of VEGF-A mRNA injections in relation to the microdialysis probe in the rabbit study. For further details, see methods.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Placement of VEGF-A mRNA injections in relation to the microdialysis probe in the pig study. For further details, see methods.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Concentrations of human VEGF-A in eluates from 100 kDa microdialysis probes intradermally inserted in the rabbit hind leg. Microdialysis was started at t=0 h and four id injections of VEGF-A mRNA injections (50 μ g each) were given at t=1 h. Dotted line indicates Lower Limit of Quantification (LLOQ, 33.4 pg/mL). Two probes were inserted in each rabbit. Values shown are mean ± SEM (n=4).

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Concentrations of human VEGF-A in microdialysis eluates from 100 kDa microdialysis probes intradermally inserted on the pig (n=3) abdomen. Values presented as individual values in eluate from each probe. Six intradermal VEGF-A mRNA injections (50 μ L each, total 24, 120, or 600 μ g VEGF-A mRNA) were given at t=0 h. At t=1.5 h after the injections, microdialysis was started. Eluates were collected during the time intervals from 1.5 h to 3.5 h, from 3.5 h to 5.5 h, and from 5.5 h to 7.5 h, respectively. Dotted vertical line indicates Lower Limit of Quantification (33.4 pg/mL); eluate samples below LLOQ are depicted as 0.5 ∗ LLOQ=16.7 pg/mL. Six probes were inserted in each pig, two probes per dose except the 120 μ g dose, where only four probes were used to assess human VEGF-A production following injection of 24 or 600 μ g VEGF-A mRNA. The remaining two probes were used to study effects following injection of citrate/saline vehicle.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques: Injection, Saline

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Amounts (pg/mg) of human VEGF-A in skin biopsies excised approximately 8 hours after intradermal injection of VEGF-A mRNA in 3 pigs. Each dose was administered as 6 (24 and 600 μ g dose) or 4 (120 μ g dose) separate injections at two different sites in each pig. Hatched data point in the 24 μ g dose, depicted at 0.1 pg/mg, indicating amount below Lower Limit of Quantification (0.28 pg/mg).

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques: Injection